BNP Paribas Financial Markets’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $331 | Hold |
68
| – | – | ﹤0.01% | 5581 |
|
|
2025
Q4 | $455 | Hold |
68
| – | – | ﹤0.01% | 5485 |
|
|
2025
Q3 | $298 | Sell |
68
-107
| -61% | -$508 | ﹤0.01% | 5354 |
|
|
2025
Q2 | $778 | Sell |
175
-6,055
| -97% | -$25.3K | ﹤0.01% | 5179 |
|
|
2025
Q1 | $35.3K | Sell |
6,230
-390
| -6% | -$4.99K | ﹤0.01% | 4394 |
|
|
2024
Q4 | $140K | Sell |
6,620
-848
| -11% | -$19.5K | ﹤0.01% | 4042 |
|
|
2024
Q3 | $201K | Sell |
7,468
-3,034
| -29% | -$89.4K | ﹤0.01% | 3254 |
|
|
2024
Q2 | $299K | Buy |
10,502
+2,905
| +38% | +$102K | ﹤0.01% | 2929 |
|
|
2024
Q1 | $322K | Buy |
7,597
+2,118
| +39% | +$95.2K | ﹤0.01% | 3081 |
|
|
2023
Q4 | $293K | Buy |
5,479
+734
| +15% | +$33.1K | ﹤0.01% | 3073 |
|
|
2023
Q3 | $204K | Buy |
4,745
+3,468
| +272% | +$160K | ﹤0.01% | 3081 |
|
|
2023
Q2 | $70.1K | Buy |
1,277
+1,268
| +14,089% | +$69.6K | ﹤0.01% | 3377 |
|
|
2023
Q1 | $391 | Sell |
9
-19
| -68% | -$564 | ﹤0.01% | 3732 |
|
|
2022
Q4 | $762 | Hold |
28
| – | – | ﹤0.01% | 3835 |
|
|
2022
Q3 | $704 | Sell |
28
-964
| -97% | -$31.9K | ﹤0.01% | 4482 |
|
|
2022
Q2 | $35.7K | Buy |
992
+320
| +48% | +$14.4K | ﹤0.01% | 3627 |
|
|
2022
Q1 | $41.7K | Sell |
672
-384
| -36% | -$22.7K | ﹤0.01% | 3588 |
|
|
2021
Q4 | $74.5K | Buy |
1,056
+301
| +40% | +$21.4K | ﹤0.01% | 3665 |
|
|
2021
Q3 | $52.7K | Buy |
755
+627
| +490% | +$49.9K | ﹤0.01% | 3509 |
|
|
2021
Q2 | $10.7K | Sell |
128
-1,668
| -93% | -$118K | ﹤0.01% | 3709 |
|
|
2021
Q1 | $98.1K | Buy |
1,796
+739
| +70% | +$35.9K | ﹤0.01% | 3362 |
|
|
2020
Q4 | $45.3K | Buy |
1,057
+183
| +21% | +$6.83K | ﹤0.01% | 3601 |
|
|
2020
Q3 | $26.3K | Buy |
874
+733
| +520% | +$24.7K | ﹤0.01% | 3734 |
|
|
2020
Q2 | $4.38K | Buy |
141
+138
| +4,600% | +$3.72K | ﹤0.01% | 4055 |
|
|
2020
Q1 | $62 | Hold |
3
| – | – | ﹤0.01% | 4234 |
|
|
2019
Q4 | $85 | Sell |
3
-400
| -99% | -$11.5K | ﹤0.01% | 4339 |
|
|
2019
Q3 | $12.4K | Hold |
403
| – | – | ﹤0.01% | 4109 |
|
|
2019
Q2 | $8.06K | Sell |
403
-354
| -47% | -$10.4K | ﹤0.01% | 4149 |
|
|
2019
Q1 | $32.6K | Buy |
757
+654
| +635% | +$23.7K | ﹤0.01% | 3739 |
|
|
2018
Q4 | $3.27K | Sell |
103
-12
| -10% | -$473 | ﹤0.01% | 3708 |
|
|
2018
Q3 | $6.03K | Sell |
115
-1
| -0.9% | -$56 | ﹤0.01% | 3965 |
|
|
2018
Q2 | $6.21K | Buy |
+116
| New | +$5.94K | ﹤0.01% | 3994 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4197 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4207 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4214 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4249 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4068 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 4147 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3532 |
|
|
2016
Q2 | – | Sell |
-116
| Closed | -$3.69K | – | 3552 |
|
|
2016
Q1 | $3.5K | Sell |
116
-500
| -81% | -$14.2K | ﹤0.01% | 2324 |
|
|
2015
Q4 | $21.4K | Sell |
616
-76
| -11% | -$2.6K | ﹤0.01% | 3267 |
|
|
2015
Q3 | $26.1K | Buy |
692
+414
| +149% | +$19.3K | ﹤0.01% | 3222 |
|
|
2015
Q2 | $15.9K | Buy |
+278
| New | +$15.8K | ﹤0.01% | 3191 |
|
|
2014
Q3 | – | Sell |
-49
| Closed | -$2.23K | – | 4175 |
|
|
2014
Q2 | $2.23K | Buy |
49
+44
| +880% | +$1.85K | ﹤0.01% | 3043 |
|
|
2014
Q1 | $203 | Sell |
5
-38
| -88% | -$1.73K | ﹤0.01% | 3210 |
|
|
2013
Q4 | $2.02K | Buy |
+43
| New | +$1.88K | ﹤0.01% | 3648 |
|
|
2013
Q3 | – | Sell |
-1,389
| Closed | -$49.8K | – | 2633 |
|
|
2013
Q2 | $49.8K | Buy |
+1,389
| New | +$53.2K | ﹤0.01% | 2668 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
BNP Paribas Financial Markets's HBIO Position: Q1 2026 in Review
BNP Paribas Financial Markets held its Harvard Bioscience (HBIO) position steady in Q1 2026 at 68 shares worth $331. The position accounts for ﹤0.01% of the portfolio, ranked #5581.
BNP Paribas Financial Markets first reported a position in HBIO in Q2 2013 and has held it in 40 quarters since. The position peaked at $322K in Q1 2024. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- BNP Paribas Financial Markets held 68 shares of Harvard Bioscience worth $331 as of Q1 2026.
- BNP Paribas Financial Markets left its Harvard Bioscience share count unchanged in Q1 2026.
- Harvard Bioscience made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5581 holding.
- BNP Paribas Financial Markets first reported a position in Harvard Bioscience in Q2 2013 and has held it in 40 quarters since.
- BNP Paribas Financial Markets's Harvard Bioscience position peaked at $322K in Q1 2024.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.